Plant Name: Capparis ovata
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 7.645E-10 | 1.110E-06 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, PPARA, PPARD |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 5.070E-08 | 5.810E-05 | FABP2, FABP3, FABP4, FABP5 |
| MF | GO:0005215; transporter activity | GO:0005412; glucose:sodium symporter activity | 6.067E-08 | 6.605E-05 | SLC5A1, SLC5A2, SLC5A4 |
| BP | Unclassified; | GO:0015758; glucose transport | 6.399E-07 | 5.806E-04 | PPARD, SLC5A1, SLC5A2, SLC5A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.349E-29 | 2.937E-25 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | Unclassified; | GO:0035428; hexose transmembrane transport | 4.596E-06 | 2.944E-03 | SLC5A1, SLC5A2, SLC5A4 |
| BP | GO:0051179; localization | GO:1904659; glucose transmembrane transport | 4.596E-06 | 2.944E-03 | SLC5A1, SLC5A2, SLC5A4 |
| BP | Unclassified; | GO:1905950; monosaccharide transmembrane transport | 4.596E-06 | 2.944E-03 | SLC5A1, SLC5A2, SLC5A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 6.523E-06 | 3.689E-03 | CA2, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 7.393E-23 | 8.049E-19 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.502E-21 | 1.362E-17 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 8.327E-29 | 7.245E-27 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 6.024E-10 | 2.621E-08 | FABP2; FABP3; FABP4; FABP5; PPARA; PPARD |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.466E-04 | 4.252E-03 | CA2; SLC5A1; CYP3A4 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 5.040E-04 | 1.096E-02 | CA2; CA4 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 2.930E-03 | 3.354E-02 | PPARA; NFKB1; TSHR |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 2.874E-03 | 3.354E-02 | NFKB1; TLR2 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 3.084E-03 | 3.354E-02 | NFKB1; PPARD |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 2.978E-03 | 3.354E-02 | FABP4; TSHR |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 3.990E-03 | 3.857E-02 | NFKB1; TLR2 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 4.612E-03 | 3.959E-02 | PPARA; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 5.006E-03 | 3.959E-02 | NFKB1; TLR2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA1; CA9; NFKB1; TLR2 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; TLR2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| NA: NA | Dyslipidemia | NA | PPARD |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | SLC5A2; PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | SLC5A4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | SLC5A1; SLC5A2; SLC5A2; NFKB1; SLC5A4; PPARD |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | SLC5A1; SLC5A2; SLC5A4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | SLC5A2 |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1 |